Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 29, 2017
Pharmacy Choice - News - Pharmaceutical Development - May 29, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/28/17 - Findings from Bentley University Broaden Understanding of Clinical Trials and Studies (Timelines of translational science: From technology initiation...
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Current study results on Clinical Research- Clinical Trials and Studies have been published. We examined timelines of translational science for 138 drugs and biologicals approved by the FDA from 2010-2014 using an analytical model of technology maturation. " Our news journalis
5/28/17 - Safety events common for pharmaceuticals and biologics after FDA approval
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Among more than 200 new pharmaceuticals and biologics approved by the U.S. Food and Drug Administration from 2001 through 2010, nearly a third were affected by a postmarket safety event such as issuance of a boxed warning or safety communication, according to a study published
5/27/17 - Abide Therapeutics Announces Dosing of First Subject in fMRI Imaging Study to Investigate Brain Activity Patterns Associated with ABX-1431
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Abide Therapeutics, a developer of innovative pharmaceuticals, announced initiation of dosing in a Phase 1 study using functional magnetic resonance imaging to evaluate patterns of neural activity in the brain associated with oral administration of ABX-1431, a first-in-class.
5/27/17 - Accelerated FDA approval and pricey drugs make a rotten combo, doctors argue [Tehran Times (Iran)]
Should drugs that win FDA approval on an accelerated pathoften without strong evidence of efficacycommand the same high prices as products that undergo the full menu of agency scrutiny? The ideaswhich include lower prices until drugs prove themselves out in confirmatory trialscome amid an unprecedented debate over the price tags on drugs in the U.S
5/27/17 - BioCryst gets a big boost from its latest HAE data, but it still faces a dangerous high wire act and giant rivals [Tehran Times (Iran)]
A little more than a year ago, shares of Research Triangle Park, NC- based BioCryst$ BCRX were crushed by a failed Phase II trial for their lead drug for hereditary angioedema, or HAE. Setbacks like that are not new for BioCryst. But the biotech turned to another HAE drug coming up the pipeline.
5/27/17 - Calcimedica gets fast track status for CRAC channel inhibitor `CM4620` to treat acute pancreatitis [Tehran Times (Iran)]
Privately-held CalciMedica, announced that it received Fast-Track designation from the US Food and Drug Administration for its lead clinical compound, CM4620, a novel, calcium release-activated calcium channel inhibitor, for the treatment of acute pancreatitis. "We are very pleased to receive Fast-Track designation for CM4620, which may allow us t
5/27/17 - Cancer scientist tries to help others as he battles his own Stage 4 cancer [The San Diego Union-Tribune]
The lanky, low-key and bearded Point Loma Heights resident has a doctorate in medicinal chemistry and is the co-inventor of Zykadia, an FDA- approved lung cancer drug made by his employer, the massive Switzerland- based pharmaceutical company, Novartis. Four years later, that personal project, with the help of the advocacy group Fight Colorectal Ca
5/27/17 - Glenmark gets USFDA`s approval to sell generic blood pressure medicine [Sudan Tribune]
Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for its generic version Olmesartan Medoxomil Tablets, used in treatment of high blood pressure. The approval granted by the US Food and Drug Administration to Glenmark Pharmaceuticals Inc is for multiple strengths of 5 mg, 20 mg and 40 mg, the company sa
5/27/17 - Global Peptide Therapeutics Market & Clinical Trials Insights, 2022 [Sport360]
-Research and Markets has announced the addition of the "Global Peptide Therapeutics Market& Clinical Trials Insight 2022" report to their offering. Global Peptide Therapeutics Market& Clinical Trials Insight 2022 report gives comprehensive insight into the various clinical and non-clinical issues involved in the development of global peptide drug.
5/27/17 - Guangzhou receives Chinese approval for clinical trials of KX-02 for glioblastoma [Syrian Arab News Agency]
Athenex, a global specialty oncology pharmaceutical company focusing on the development and commercialization of next generation therapies for cancers and supportive therapies, announced that its partner, Guangzhou Xiangxue Pharmaceutical Co. Ltd., has received the Chinese FDA Investigational New Drug approval to begin clinical trials for KX-02...
5/27/17 - GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Groundbreaking Study of Epidiolex (cannabidiol) in The New England Journal of Medicine [Sudan Tribune]
GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex in...
5/27/17 - Kalytera Announces Changes to its Board of Directors [Palestine News Network]
-Kalytera Therapeutics, Inc., a clinical-stage pharmaceutical company developing cannabinoid therapeutics for Graft versus Host Disease, today announced the appointment of Ronald P. Erickson as Interim Chairman of its Board of Directors. Kalytera also announced the resignations of Jerome B. Zeldis, M.D., Ph.D., Director, and David Stefansky, Chairm
5/27/17 - Kite catches the inside track on the last leg of a race to the finish line with Novartis on a CAR-T first [T-break Tech (Middle East)]
The race between Novartis$ NVS and Kite$ KITE to win the first FDA approval of a CAR-T for cancer is now in the final stretch, and Kite just shortened its distance to the finish line. The biotech announced this morning that the FDA is providing a priority review for their drug KTE-C19, which will cut the time it takes for regulators to complete the
5/27/17 - McCaskill, Collins Effort to Tackle Cost of Rx Drugs Clears Key Committee Hurdle
Claire McCaskill, D- Mo., issued the following news release:. A bipartisan plan from U.S. Senator Claire McCaskill and Republican Senator Susan Collins of Maine to combat the sudden, aggressive price hikes of generic drugs by promoting competition to help lower costs and improve accessibility cleared a key committee hurdle today and now advances to
5/27/17 - New FDA Commissioner reveals strategy to drive down drug prices [Tehran Times (Iran)]
According to Gottlieb, the FDA is currently working on a drug competition action plan which is designed particularly to accelerate the approval of generic drugs which face no competition. Gottlieb told a congressional panel that he aims for the FDA to take a more active role in the pricing of drugs, noting: While FDA does not play a direct role in
5/27/17 - Novartis receives FDA approval for expanded use of Zykadia in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC) [Sport360]
-In ALK-positive metastatic NSCLC patients, Zykadia median progression-free survival was 16.6 months, compared to 8.1 months with chemotherapy. Basel, May 26, 2017- Novartis today announced the US Food and Drug Administration approved the expanded use of Zykadia to include the first-line treatment of patients with metastatic non-small cell lung can
5/27/17 - OncoQuest to present phase II clinical results of Oregovomab for treatment of ovarian cancer at ASCO annual meet [Syrian Arab News Agency]
OncoQuest, a privately held, biopharmaceutical company focused on the development and commercialization of immunotherapeutic products for the treatment of cancer, has announced the presentation of initial safety and efficacy data from the companys multicenter, randomized phase 2 study in patients with newly diagnosed advanced ovarian cancer at the.
5/27/17 - Regeneron Announces ANGPTL3/Evinacumab Publication in New England Journal of Medicine and Positive Phase 2 Data in People with HoFH [Syrian Arab News Agency]
Regeneron Pharmaceuticals, Inc. today announced new data from genetics, preclinical and clinical studies supporting the continued development of evinacumab, its investigational angiopoietin-like 3 antibody. An analysis published today in the New England Journal of Medicine showed that people with inactivating mutations of the ANGPTL3 gene have...
5/26/17 - Abbott Labs: A genomic disease management company, engages in the development and marketing of clinical laboratory products, which provide information critical to the evaluation and management of cancer, prenatal disorders, and other genetic diseases
It currently markets seven U.S. Food and Drug Administration or foreign cleared or approved clinical products in addition to distributing over 300 Analyte Specific Reagent and research products through its direct sales operations in the United States and Europe and a worldwide distribution network covering 59 countries. Mary Szela joined Melinta...
5/26/17 - Abeona Therapeutics receives FDA orphan designation for gene therapy
The FDA has granted Orphan Drug Designation for Abeona Therapeutics's EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa...
5/26/17 - Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa [Tehran Times (Iran)]
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that the FDA has granted Orphan Drug Designation for Abeonas EB-101 gene therapy program for patients with dystrophic epidermolysis bullosa, including recessive dystrophic...
5/26/17 - Active Pharmaceutical Ingredients Market Outlook and Worldwide Forecast to 2027
Global Active Pharmaceutical Ingredients Information, by types, by applications, by manufacturing method-Forecast 2027 Pune, India 05/26/2017 Market Synopsis of Active pharmaceutical ingredients Market:. Active Pharmaceutical Ingredient is the integral part of the drug because of which the disease gets cured. Request a Sample Report@...
5/26/17 - Advanced Accelerator Applications (AAAP) Appoints Christine Mikail to Board of Directors [National News Agency (Lebanon)]
Advanced Accelerator Applications S.A. today announced that Christine Mikail, J.D. has joined the Companys board of directors as an independent non-executive director. Ms. Mikail brings both a broad legal skillset and substantial business development experience in the pharmaceutical industry, stated Stefano Buono, Chief Executive Officer of AAA.
5/26/17 - AERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI [Sport360]
Today`s Daily Dose brings you news about Aerie Pharma`s positive efficacy results from phase III study of its glaucoma drug candidate Roclatan; Alnylam`s public offering and FDA panel`s support for approval of Puma`s breast cancer drug Neratinib. Shares of Aerie Pharmaceuticals Inc. climbed more than 27% in extended trading on Wednesday, following.
5/26/17 - Agency Information Collection Activities: Proposed Collection; Comment Request; Applications for Food and Drug Administration Approval To Market a...
SUMMARY: The Food and Drug Administration is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415